Answers are grounded in this paper and cite their sources.
U50,488H (U50) is a κ‐opioid receptor agonist exerting effective analgesia in animal pain models. Yet, side effects such as sedation and depression‐like symptoms mediated in the brain limit its therapeutic potential. In this study, tailor‐made core‐multishell (CMS) nanocarriers are presented containing U50 that, despite their small size, exhibit a pH‐dependent retention effect via non‐covalent interactions with the drug. The nanocarriers and their non‐functionalized counterparts are characterized regarding their release properties in vitro, including a theoretical modeling of the release parameters which show the beneficial features of the additional functionalization. Finally, the U50‐containing nanocarriers are tested in an in vivo rat model of inflammatory pain, with the results showing prolonged analgesic effect.
No takes yet. Share an insight, caveat, or question.
Unbehauen et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: